NCT00916981

Brief Summary

Treatment of nonunion, delayed union and malunion fractures of long bones remains problematic. The definition of nonunion is a failure of the fracture to heal in six months in a patient in whom progressive repair had not been observed radiographically between the third and sixth month after the fracture. First of all good surgical techniques are stable immobilization must be obtained and local sepsis excluded. Then stimulation of the callus is required. Numerous techniques have been developed ranging from invasive interventions (including internal fixation with the use of bone graft or bone graft substitutes) to non invasive procedures (ultrasound and pulsed electromagnetic fields). Recently, autologous cell therapy was presented as an interesting approach. The concept of such therapies is based on the effect of stem cells presented in the bone marrow and able to be transformed in osteoblast cells. The percutaneous technique of autologous bone-marrow grafting is a minimally invasive alternative able to produce a good healing of the fracture. The efficacy is dependent of the concentration in progenitor cell reinjected. An optimization of this type of treatment could be achieved using a technique to increase the differentiation of the bone marrow cells in preosteoblasts before the injection in situ by an adequate culture. Therefore we would like to start a pilot open study on the feasibility and the efficacy of implantation of preosteoblasts into nonunion. Two different presentations exist: the atrophic and the hypertrophic pseudarthrosis in relationship with radiological features of bone proliferation at the tip of bone fragments. Some data support that atrophic and hypertrophic nonunion fractures could have different physiopathological factors. So, in a first time we only would evaluate the atrophic form and to determine in an open study the effect of the implantation of preosteoblasts into atrophic nonunion.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at P25-P50 for phase_1

Timeline
Completed

Started Nov 2008

Shorter than P25 for phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2008

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2009

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

June 3, 2009

Completed
7 days until next milestone

First Posted

Study publicly available on registry

June 10, 2009

Completed
Last Updated

February 23, 2012

Status Verified

February 1, 2012

Enrollment Period

7 months

First QC Date

June 3, 2009

Last Update Submit

February 22, 2012

Conditions

Keywords

pseudarthrosisTreatmentosteoblast graftingcell therapynonunion

Outcome Measures

Primary Outcomes (1)

  • radiological progression of bone fusion

    monthly

    1, 2, 3, 4, 5, 6 months

Secondary Outcomes (1)

  • reduction of pain using VAS

    each month

Interventions

percutaneously injection of preosteoblast into the nonunion under radioscopic control

Also known as: PREOB

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Fracture of a long bone having insufficient healing after minimum 6 months.
  • Be able and willing to participate in the study.

You may not qualify if:

  • Evidence of malignant disorder in the past five year.
  • Patient who is positive for an HIV, hepatitis B or C infection.
  • Insufficient reduction of the fracture with displaced fragments.
  • Evidence of local sepsis by biological parameters and/or positive isotopic scan using leucocytes labelled by Indium.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU Sart Tilman

Liège, Liège, 4000, Belgium

Location

MeSH Terms

Conditions

PseudarthrosisFractures, Ununited

Condition Hierarchy (Ancestors)

Fractures, BoneWounds and Injuries

Study Officials

  • Jean-Philippe Hauzeur, MD, PhD

    University of Liège, Belgium

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

June 3, 2009

First Posted

June 10, 2009

Study Start

November 1, 2008

Primary Completion

June 1, 2009

Study Completion

June 1, 2009

Last Updated

February 23, 2012

Record last verified: 2012-02

Locations